Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Medulloblastoma
NCT05382338Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Feb 2023
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of sodium thiosulfate in ototoxicity, sponsored by Children's Oncology Group. Primary endpoints: Percentage of patients with >= grade 2 hearing loss and Event-free survival up to 10 years. Started Feb 2023; status: recruiting.
02
Drugs
sodium thiosulfate
03
Conditions
ototoxicity
Beyond the preview
Go deeper on NCT05382338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382338.